The evaluation of efficacy and safety in modification to new immunosuppressant (tacrolimus hydrate:Graceptor) from the current immunosuppressive therapy after liver transplantatio
Phase 4
- Conditions
- Adult Recipients after liver transplantation
- Registration Number
- JPRN-UMIN000001649
- Lead Sponsor
- Graduate School of Medicine, Osaka University Department of Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1clinicopathologically diagnosed with rejection in recent 90 days . 2underwent rejection treatment in recent 6 months 3diagnosed with rejection beyond twice in 12 months 4liver dysfunction ,AST>=40, or ALT>=40 5Drug user of cross interaction with Tacrolimus 6Other severe concomitant disease or medical conditions. 7drug abuser, mentally unstable recipient, The patient who was judged to have difficulty in communication with the doctor 8History of contraindication to tacrolimus. 9A pregnant woman or a woman with possibility becoming pregnant 10severe renal dysfunction 11Inappropriate patients for entry on this trial in the judgement of the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method